protected. ANOVA analysis evaluated differences among CAPs and in each CAP value among the 3 groups. MANOVA multivariate analysis evaluated differences in overall CAPs and the effects of age, gender, Mueller grade and stings number. A P , 0.05 was considered statistically significant. Data were analysed by 'SPSS' 13.0 (SPSS Inc., Chicago, IL). We called NS patients to check if they were stung after VIT discontinuation. Results: We selected 84 NS, 72 SP3 and 76 SP5 patients. Specific YJ-IgE levels decreased during VIT, as CAPs are statistically different at time 0, 3 and 5 (P , 0.001). Considering CAP levels at the first control (CAP3), NS patients presented lower values than SP3 patients (P ¼ 0.002); no significant difference was found between NS and SP5 patients. At the last control (CAP5), CAP values of NS and SP5 patients were different (P ¼ 0.002) as well as between SP3 and SP5 patients (P ¼ 0.014). No significant difference was found between NS and SP3 patients. By MANOVA, IgE decrease was inversely correlated with Mueller grade (P ¼ 0.012) and age (P ¼ 0.002). We recalled all NS patients by phone, 7/84 (8.3%) patients related one well tolerated sting, as they did not develop any allergic reaction. Conclusions: In everyday practice if a patient never stung during VIT fulfils the temporal criterion, but specific IgE are not negative, a decrease of IgE levels ranging from 57 to 70% in respect to baseline might be a satisfactory parameter for stopping VIT. As a further confirmation of our conclusions, even if not statistically significant, all not stung patients were clinically protected after VIT discontinuation.
Background: The worldwide prevalence of allergic reaction to mosquito bites is unknown. Some patients who suffer from local reactions have also systemic symptoms. Methods: A 3 year old female who suffered from mosquitoes bites in her left lower extremity, had a large local reaction with erythema, edema, itching, pain and blisters of 5 · 6 cm. It was accompanied by fever of 38.58C and emesis. She had a positive skin prick test for Aedes aegypti with diagnosis of Skeeter Syndrome. The patient was treated with antihistamine during 10 days and analgesics for 3 days. She was given antihistamine treatment for 10 days and analgesics for 3 days. Results: Skeeter syndrome is defined as a large local reaction induced by mosquito bites associated with systemic symptoms (fever and vomiting) with specific IgE for mosquito identified by skin testing. The primary management of Skeeter syndrome is prevention of mosquito bites, the use of repellents and protective clothing. It is also important the symptomatic management control of pruritus with the use of antihistamines or if necessary topical steroids. Overall children with Skeeter syndrome remain healthy, except for the recurrence of large local reactions to mosquito Stings. Conclusions: The early recognition of Skeeter syndrome is important to give the right management and to prevent unnecessary diagnostic tests and treatments that can increase the risk of adverse reactions and costs. Background: Bee venom immunotherapy is a safe and effective treatment, indicated in patients with previous history of severe systemic reactions to bee venom, demonstrating succesful desensitization in more than 90% of cases with standardized extract. Currently in Mexico there is no standardized extract commercially available for treatment, despite of having high activity of beekeeping and occupational exposure with at least 17,478 registered stings per year and an annually honey production of nearly 70 tons. Methods: We present the clinical progress of 2 patients with history of severe systemic reactions to bee venom and occupational exposure, both with demonstrated sensitization by specific IgE and who underwent specific immunotherapy with standardized extract (Alk-US) reaching a maintenance weekly dose of 100 mcg (PLA 2 ) for the last 4 years. Results: Both patients sufered of accidental stings after reached the maintenance dose presenting mild local reactions to stings. Both patients had very different clinical course presenting a wide variety of adverse reactions during desensitization protocol; from mild local to generalized reactions all generally well tolerated allowed to reach the maintenance dose with succesful desensitization proved by accidental exposure without severe systemic reactions. Conclusions: Bee venom specific immunotherapy with standardized extract is a well tolerated and efective treatment preventing the development of life threathening reactions in sensitized patients. It is important to promote the use and availability of standardized extract in developing countries with poor safety measures and high occupational exposure.
Clinical Case. Bee Venom Anaphylaxis
Adriana Barreto-Sosa, MD, Andrea Aida Velasco-Medina, MD, AndresLeonardo Burbano-Ceron, MD, Aida Gonzalez-Carsolio, MD, and Guillermo Velázquez-Sámano, MD. Servicio de Alergia e Inmunología Clínica, Hospital General de México, Mexico City, Mexico. Background: Skin testing remains the principal confirmatory test for sensitization to hymenopteravenoms. Mechanisms on how venom induces vascular permeability in the skinfollowing intradermal testing are elucidated and how tolerance is induced followinghigh-dose venom exposure. For management, venom immunotherapy remains the mosteffective treatment. Use of immunotherapy in large local reactors to reduce morbidity is discussed. Baseline serum tryptase levels have been identified as one potential markerfor severe systemic reactions to a subsequent sting. Bee venom immunotherapy is effective in most patients immediately after the conventionalmaintenance dose has been reached. In the minority of patients who are not protected withthis dose, an increased maintenance dose will provide appropriate protection immediately after itis achieved usually by 3 to 6 months withstandarding protocols. Thus, the dosage of the maintenance dose seems to be the major factor affectingprotection from re-stings rather than the accumulated venom dose or the durationon the Maintenance Dose. A rush protocol would be recommendedif the patient's risk of being stung againbefore standard immunotherapy could work wereconsidered high. Although immunotherapy is oftenadministered by allergists, it may be deliveredby any practitioner who is willing to observe the patientand to treat anaphylaxis if it should occur. Methods: A 17-year-old man reported being stung by a bee in his workplace. He had been stung several times before, with no clinical manifestations. This last time, he developed face edema, respiratory distress, dyspnea, vomiting recieveing treatment with hydrocortisone. Some time later, he was stung another time, presenting more severe symptoms including dyspnea, stridor, altered mental status, hives, so he was taken to a local clinic where he received epinephrine, dextrose, was hospitalized 4 hours until clinical remission. How should his case be managed subsequently? Results: Intradermal test was positive with a dilution 1:200000.
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